ARBUTUS BIOPHARMA CORP (ABUS:NASDAQ)
$4.6 -0.04 (-0.8621%)
Analysed ARBUTUS BIOPHARMA CORP (ABUS:NASDAQ) News Sources
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
15-04-2026
yahoo.com
Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability
17-04-2026
yahoo.com
Arbutus Biopharma (ABUS) Wins FDA Fast Track for Imdusiran
23-04-2026
yahoo.com
Arbutus Biopharma (ABUS): 10 Best Biotech Penny Stocks to Buy in 2026
01-05-2026
yahoo.com
Moderna sees revenue bump from international COVID vaccine sales
01-05-2026
biopharmadive.com
Moderna Q1 2026 earnings beat on international COVID vaccine sales
01-05-2026
qz.com
Moderna Reports Q1 Loss, Stock Jumps on Strong International Sales
01-05-2026
yahoo.com
Moderna’s Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway.
01-05-2026
yahoo.com
The Zacks Analyst Blog Highlights Moderna, Merck and Vertex Pharmaceuticals
04-05-2026
yahoo.com
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
13-05-2026
yahoo.com
What is the current price of ARBUTUS BIOPHARMA CORP (ABUS:NASDAQ)?
The current price of ARBUTUS BIOPHARMA CORP (ABUS:NASDAQ) is $4.6.
ARBUTUS BIOPHARMA CORP (ABUS:NASDAQ) absolute price change since previous trading day?
The absolute price change of ARBUTUS BIOPHARMA CORP (ABUS:NASDAQ) since the previous trading day is $-0.04.
ARBUTUS BIOPHARMA CORP (ABUS:NASDAQ) percentage price change since previous trading day?
The percentage price change of ARBUTUS BIOPHARMA CORP (ABUS:NASDAQ) since the previous trading day is -0.8621%.
What is the most recent average sentiment score for ARBUTUS BIOPHARMA CORP (ABUS:NASDAQ)?
The most recent average sentiment score for ARBUTUS BIOPHARMA CORP (ABUS:NASDAQ) is 58 out of 100.
What is the most recent average sentiment for ARBUTUS BIOPHARMA CORP (ABUS:NASDAQ)?
The most recent sentiment for ARBUTUS BIOPHARMA CORP (ABUS:NASDAQ) is .
SEC-8K** Filing Available For ARBUTUS BIOPHARMA CORP (ABUS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.